Daily FNArena News

Investment U’s Matthew Carr predicts a mega take-over deal, or two, in the copper space, and soon.

Daily update on share prices and consensus price targets.

US equities have further to correct, says Dennis Gartman, with conviction.

Thorn Group posted a full year profit at the top end of guidance and with further growth from a broader base expected in coming years brokers continue to see value.

Starpharma should generate first revenues from its VivaGel product this year and Southern Cross sees further upside as the company continues to develop its dendrimer technology.

Daily update on share prices and consensus price targets.

A booming dotcom listing leads PFP Wealth Management’s Tim Price to caution equity markets are not cheap at present relative to known threats.

A glance through the latest expert views and predictions about commodities with NAB seeing little correlation between commodity prices and QE, support for gold and copper, caution on silver, and gems as investments.

REVA Medical is developing bioresobable stents for treating coronary artery disease and Southern Cross rates the stock a Spec Buy.

The spot uranium price drifted back last week once the market gave up on its hope that a single buyer was prepared to buy all of the US government’s selling order.